Gå direkt till innehåll
MetaboGen is granted US diabetes patent

Pressmeddelande -

MetaboGen is granted US diabetes patent

MetaboGen AB has on January 30th, 2018 been granted a US patent for the identification of a person at risk for developing type 2 diabetes using metagenomic sequence data from the GI-tract.

The human intestinal tract is inhabited by 10-100 trillion of microbes comprised of thousands of different species, collectively called the microbiota. This microbial community has an immense capacity to affect host biology. Imbalance in the gut microbiome is associated with multiple diseases and unhealthy conditions. The microbiome thus holds great potential to provide the industry with new opportunities to understand and tackle health issues for the benefit of patients.

- We are very pleased to have been granted this patent in the important diabetes area, Sara Malcus, CEO of MetaboGen says.

For more information, please contact:

Sara Malcus, CEO MetaboGen AB
Email: sara.malcus@metabogen.com
Phone: +46 705-82 32 22

About MetaboGen AB

MetaboGen is a research-driven company with a focus on the microbiome and its impact on health, based in Gothenburg, Sweden. The company was founded based on break through science from the labs of Professor Fredrik Bäckhed (University of Gothenburg) and Professor Jens B Nielsen (Chalmers University of Technology). Since 2011, MetaboGen develops products based on advanced mapping of the intestinal microflora composition. In 2014 BioGaia AB invested in the company. MetaboGens technology along with more than 25 years of experience in the development of probiotics from BioGaia, provides the company with a unique opportunity to develop the next generation of microbial products. MetaboGen has its headquarters and laboratory at the AstraZeneca BioVenture hub, Mölndal, Sweden. For more information see www.metabogen.com

GU Ventures shares news and information about all our companies and alumni.

Relaterade länkar




About GU Ventures

GU Ventures AB is fully owned by the Swedish government and is managed since 1998 by the University of Gothenburg. The mission is to commercialise ideas in connection to the operations at the University of Gothenburg and to deliver economic and social benefits. To ensure this, GU Ventures builds and invests its own funds in new businesses, which are actively supported in the GU Ventures incubator that provides business development and administrative support. With over 140 new businesses established, that have lead to 30 exits and 11 IPOs already for GU Ventures. UBI Global Index has top ranked GU Ventures for its incubation and investment operations. Please visit: www.guventures.com


Sara Malcus

Sara Malcus

VD MetaboGen AB +46 (0)705 823222

GU Ventures AB
Erik Dahlbergsgatan 11A vån 2
41126 Göteborg